Celldex’s Cdx-622 Shows Promise in Preclinical Inflammatory Disease Study
Celldex Therapeutics announced positive preclinical data for CDX-622, a bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and stem cell...
eClinical Tech News
Voyager Reports Positive Topline Anti-Tau Antibody Data, Initiates Next Trial
Voyager Therapeutics announced positive topline data from its single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody...
Traws Pharma Reports Positive Bird Flu Results for Tivoxavir
Traws Pharma announced positive topline results from a ferret study of tivoxavir marboxil, a single-dose oral antiviral for bird...
Deucrictibant Data at AAAAI/WAO 2025: HAE Prevention & Treatment
Pharvaris released positive long-term data for its oral bradykinin B2 receptor antagonist, deucrictibant, at the 2025 AAAAI/WAO Joint Congress....
Apg990 Interim Phase 1 Results Show Potential for Maintenance Dosing
Apogee Therapeutics announced positive interim Phase 1 results for APG990, a novel, half-life extended OX40L antibody, demonstrating an approximately...
Lexicon Announces Pilavapan Results for Diabetic Nerve Pain
Lexicon Pharmaceuticals will announce topline results from its Phase 2b PROGRESS study of pilavapadin (LX9211) for diabetic peripheral neuropathic...
Milestone Reached: First Patient Treated with EG110A for Neurogenic Bladder
EG 427 has dosed the first patient in its Phase 1b/2a clinical trial of EG110A, a novel gene therapy...
Derm-Biome’s DB-007-5 Highly Effective in Atopic Dermatitis Study
Derm-Biome Pharmaceuticals announced positive preclinical results for its topical drug DB-007-5 in treating atopic dermatitis (AD). The drug significantly...
Sonnet BioTherapeutics Son-1010: Improved Solid Tumor Treatment
Sonnet BioTherapeutics presented data at the 2025 AACR:IO Conference on its Fully Human Albumin Binding (FHAB) platform, which enhances...
First Participant Dosed in Phase 1a Study of Oral HDV Entry Inhibitor
Assembly Biosciences has dosed the first participant in a Phase 1a clinical trial for ABI-6250, an oral HDV entry...